Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | BUB1 | O43683 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13984639 | 1.00 | EPHA2 (0.50) | EPHA2PDK1ERBB2EPHB4MEN1 | |
| SCHEMBL12661156 | 0.91 | EPHA2 (0.48) | EPHA2PDK1ERBB2EPHB4P2RX3 | |
| SCHEMBL1852171 | 0.90 | PDK1 (0.51) | EPHA2PDK1ERBB2EPHB4MEN1 | |
| SCHEMBL13984286 | 0.90 | PDK1 (0.48) | EPHA2PDK1ERBB2EPHB4P2RX3 | |
| SCHEMBL12661155 | 0.88 | PDK1 (0.49) | EPHA2PDK1ERBB2EPHB4MEN1 | |
| SCHEMBL24933225 | 0.87 | EPHA2 (0.58) | EPHA2PDK1ERBB2EPHB4P2RX3 | |
| SCHEMBL30915187 | 0.85 | EPHX2 (0.52) | EPHA2PDK1ERBB2EPHB4P2RX3 | |
| SCHEMBL31712327 | 0.85 | EPHX2 (0.52) | EPHA2PDK1ERBB2EPHB4P2RX3 | |
| SCHEMBL15058458 | 0.82 | EPHA2 (0.52) | EPHA2PDK1ERBB2EPHB4MEN1 | |
| SCHEMBL3023357 | 0.82 | XDH (0.48) | EPHA2PDK1ERBB2EPHB4P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | EPHA2 4801/4885PDK1 255/4885ERBB2 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.